|Summary sheet: Proscaline|
|Routes of Administration|
4-Propyloxy-3,5-dimethoxyphenethylamine (also known as proscaline) is a lesser-known psychedelic substance of the phenethylamine class. It is a structurally related to mescaline and belongs to a series of mescaline analogs that include isoproscaline, escaline and allylescaline.
The synthesis of proscaline was first published by David E. Nichols in 1977. Around the same time, Alexander Shulgin sampled and evaluated the chemical at doses up to 60 mg, estimating its potency as five times that of mescaline. Shulgin later documented his findings in the 1991 book PiHKAL ("Phenethylamines I Have Known and Loved"). Proscaline appeared for sale on the online research chemical market in the 2010s.
Subjective effects are similar to mescaline and include open and closed-eye visuals, time distortion, enhanced introspection, conceptual thinking, euphoria, and ego loss. However, it is reported to produce significantly less visual effects, euphoria, and ego loss than mescaline. As a result of its limited recreational potential, demand for the substance is relatively limited. It may have potential utility as an adjunct in psychedelic therapy, although this has yet to be explored.
Very little data exists about the pharmacological properties, metabolism, and toxicity of proscaline. It is assumed to have a risk profile similar to mescaline, although this has not been confirmed in studies. It is highly advised to use harm reduction practices if using this substance.
Proscaline, or 3,5-dimethoxy-4-propyloxyphenethylamine, is a substituted phenethylamine featuring a phenyl ring bound to an amino -NH2 group through an ethyl chain. Proscaline contains two methoxy functional groups CH3O- which are attached to carbons R3 and R5 as well as an additional propyloxy group at carbon R4 of the phenyl ring. Proscaline is the 4-propyloxy analog of mescaline, which means it has one additional carbon at the alkyloxy group than escaline, another closely related mescaline analog.
Proscaline's psychedelic effects are believed to come from its efficacy at the 5-HT2A receptor as a partial agonist. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.
|This subjective effects section is a stub.|
As such, it is still in progress and may contain incomplete or wrong information.
You can help by expanding or correcting it.
Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), a research literature based on anecdotal reports and the personal experiences of PsychonautWiki contributors. As a result, they should be regarded with a healthy degree of skepticism. It is worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become much more likely with higher doses and may include addiction, serious injury, or death.
- Drifting (melting, breathing, morphing and flowing)
- Colour shifting
- Depth perception distortions
- Perspective distortions
- Symmetrical texture repetition
- After images
- Brightness alteration
There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:
Toxicity and harm potential
The toxicity and long-term health effects of recreational proscaline use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. Anecdotal evidence from people who have tried proscaline within the psychedelic community suggests that there are no negative health effects attributed to trying this drug, but nothing can be completely guaranteed.
It is strongly recommended that one use harm reduction practices when using this drug.
Tolerance and addiction potential
Proscaline is not habit-forming, and the desire to use it can actually decrease with use. It is most often self-regulating.
Tolerance to the effects of proscaline is built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). proscaline presents cross-tolerance with all psychedelics, meaning that after the consumption of proscaline all psychedelics will have a reduced effect.
This legality section is a stub.
As such, it may contain incomplete or wrong information. You can help by expanding it.
- Germany: Proscaline is controlled under the NpSG (New Psychoactive Substances Act) as of November 26, 2016. Production and import with the aim to place it on the market, administration to another person, placing it on the market and trading is punishable. Possession is illegal but not punishable. The legislator considers it possible that orders of proscaline are punishable as an incitement to place it on the market.
- Switzerland: Proscaline can be considered a controlled substance as a defined derivative of Phenethylamine under Verzeichnis E point 130. It is legal when used for scientific or industrial use.
- United Kingdom: Proscaline is a Class A controlled substance as it is covered by the phenethylamine derivatives clause of the Misuse of Drugs Act of 1971.
- United States: Proscaline is uncontrolled in the United States.
- Alexander Shulgin; Ann Shulgin (1991). "#140. P". PiHKAL: A Chemical Love Story. United States: Transform Press. ISBN 0963009605. OCLC 1166889264.
- Nichols, D. E.; Dyer, D. C. (1977). "Lipophilicity and serotonin agonist activity in a series of 4-substituted mescaline analogs". Journal of Medicinal Chemistry. 20 (2): 299–301. doi:10.1021/jm00212a022. eISSN 1520-4804. ISSN 0022-2623. OCLC 39480771. PMID 836502.
- Alexander Shulgin (1980). Pharmacology Notes II (The Shulgin Lab Books) (PDF). Lafayette, CA: Erowid. p. 209.
- "Anlage NpSG" (in German). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019.
- "Gesetz zur Bekämpfung der Verbreitung neuer psychoaktiver Stoffe" (PDF). Bundesgesetzblatt Jahrgang 2016 Teil I Nr. 55 (in German). Bundesanzeiger Verlag (published November 25, 2016). November 21, 2016. pp. 2615–2622. ISSN 0341-1095. OCLC 1004462279.
- "§ 4 NpSG" (in German). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019.
- "§ 3 NpSG" (in German). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019.
- "Gesetzentwurf der Bundesregierung: Entwurf eines Gesetzes zur Bekämpfung der Verbreitung neuer psychoaktiver Stoffe" (PDF) (in German). Deutscher Bundestag. May 30, 2016. p. 20. Drucksache 18/8579.
- "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.